半夏白术天麻汤合温胆汤治疗痰湿壅盛型高血压病的临床研究
|
摘要
目的
本临床采用双盲随机对照试验,探讨半夏白术天麻汤合温胆汤加减治疗高血压痰湿壅盛证的临床有效性和安全性,进而为痰湿壅盛证方证相应研究提供临床依据。
方法
研究对象选取自2008年11月至2009年12月到台湾崇光中医门诊就诊的高血压病人60例。西医诊断按照《1999年WHO／ISH高血压治疗指南》中的高血压病诊断及分级标准执行；中医诊断参照2000年《中医新药临床研究指导原则》(试行)中的高血压病辨证标准及中医症状分级量化标准。以痰湿壅盛型为主证的高血压病患者60例均符合上述诊断标准,分级属Ⅰ～Ⅱ级。排除继发性高血压,合并有肝、脑、心、肾和造血系统严重原发疾病者。按照1：1的比例采用简单随机法实施随机分组,治疗组采用与痰湿壅盛证相对应的半夏白术天麻汤合温胆汤加减治疗,对照组采用不对证的四君子汤治疗。两种方药均按照一日份9克装在0号胶囊里制成GMP科学中药胶囊,要求两组药物的外形、颜色、包装、服法基本一致,以保证双盲的实施。两组患者早晚各服5粒(相当于生药4.5g),1月为1个疗程。治疗前、治疗1疗程后,分别记录高血压患者的临床症状体征(眩晕、头痛、头重如裹、胸闷、呕吐痰涎等)和血压,并进行中医证候疗效和高血压疗效评定。在临床试验过程中,密切观察可能出现的不良反应症状,并须如实记录。
数据处理方法：统计方法：分类资料用χ2检验,等级资料用两样本比较采用Ridit分析,两样本均数比较用t检验,自身前后比较用配对t检验。采用Epi Data3.01软件建立数据库,SPSS17.0软件进行统计分析,Graph Pad Prism4.03软件进行统计图形绘制。
结果
本研究共有合格受试者例60例,治疗组和对照组各30例,两组平均年龄分别为57.9和60.5岁,男34例,女26例。两组治疗前年龄、性别、病程、高血压分期及中医临床症状体征分布、血压水平(收缩压、舒张压)比较,差异均无统计学意义(P>0.05)。说明两组治疗前的基线基本一致,具有可比性。
经过一个疗程的治疗后,疗效结果比较如下：
(1)两组中医证候疗效
治疗组显效率23.3%,有效率63.3%,总有效率86.7%；对照组显效率10%,有效率66.7%,总有效率76.7%。两组中医证候疗效比较,差异无统计学意义(P>0.05)。说明治疗组和对照组在改善中医症候总体疗效评分上均有较好的疗效,虽然两组之间没有差异,但说明了中医药对治疗痰湿壅盛证高血压的有效性。
(2)两组高血压疗效
Ⅰ期高血压治疗后疗效：治疗组显效率20.0%,有效率50.0%,总有效率70.0%；对照组显效率0%,有效率28.6%,总有效率28.6%。治疗组的总有效率高于对照组近45个百分点,尽管没有统计学差异,但说明半夏白术天麻汤合温胆汤相对于四君子汤,在降低Ⅰ期高血压患者血压方面略有优势。
Ⅱ期高血压治疗后疗效：第Ⅱ期高血压治疗后疗效：治疗组显效率5.0%,有效率80.0%,无效15.0%；对照组显效率0%,有效率43.5%,总有效率43.5%,两组疗效比较,差异有统计学意义(P<0.05)。治疗组治疗Ⅱ期高血压的总有效率显著高于对照组。说明半夏白术天麻汤+温胆汤可以有效降低Ⅱ期高血压。(3)临床症状体征改善程度及消失情况
治疗组治疗后,眩晕、头痛、头重如裹、胸闷、呕吐痰涎、心悸、失眠改善1级以上的高血压患者分别占90.0%、96.3%、88.5%、90.0%、80.0%、50.0%、95.5%,对照组分别为48.0%、57.1%、78.3%、83.3%、50.0%、23.1%、47.6%。两组比较,治疗组和对照组在眩晕、头痛、头重如裹、胸闷、失眠症状方面具有统计学意义(P<0.01),以治疗组疗效较好。而在呕吐痰涎、心悸方面无统计学意义(P>0.05)。可见治疗组对痰湿壅盛证高血压的临床症状体征改善均较为显著,对照组对上述症状也均有一定的改善,尤其是对头重如裹、胸闷改善较好。
临床症状消失率比较,治疗组眩晕、头痛、头重如裹、胸闷、失眠症状消失率均高于对照组(均P<0.05)；呕吐痰涎、心悸、症状消失率治疗组虽比对照组稍高,但经比较差异均无统计学意义(均P>0.05)。由此可知,半夏白术天麻汤合温胆汤加减在改善高血压痰湿壅阻型的临床症状体征均比四君子汤疗效好。
(4)治疗前后收缩压、舒张压改变情况
治疗后收缩压,治疗组平均下降2.80±2.02kpa,前后比较差异显著(P<0.01)；对照组收缩压平均下降0.80±0.32 kpa,前后比较差异有统计学意义(P<0.05)；两组组间比较,差异有统计意义(P<0.01)。
治疗后舒张压,治疗组平均下降2.86±1.14 kpa,前后比较差异显著(P<0.01)；对照组平均下降0.76±0.71 kpa,前后比较差异有统计学意义(P<0.05)；两组治疗后舒张压比较,差异有统计意义(P<0.05)。
两组均能降低高血压患者的收缩压和舒张压,治疗组比对照组疗效略高一筹。特别是治疗前后疗效显著。
(5)血压恢复正常情况
以收缩压≥21.3Kpa或／和舒张压≥12.7为标准来评价血压是否恢复正常,结果发现治疗组83.3%的患者血压恢复正常,对照组为30.0%,两组血压恢复正常的比率差异有统计学意义(P<0.01)。治疗组优于对照组,这应该就是应用方证相应的结果。
安全性评价结果：治疗前后及治疗期间均无发现任何不良反应。
结论
1.半夏白术天麻汤合温胆汤对痰湿壅盛证高血压病不同分期的疗效相似。对收缩期和舒张期的血压均有效。
2.半夏白术天麻汤合温胆汤能够有效改善痰湿壅盛证高血压病临床常见症状,特别是眩晕、头痛、头重、胸闷、呕吐痰涎、失眠等临床症状。
3.半夏白术天麻汤合温胆汤能够有效消除眩晕和头痛这两个高血压病的主要症状。
4.半夏白术天麻汤合温胆汤治疗痰湿壅盛证高血压病具有安全有效的特点,同时与四君子汤相比,应用半夏白术天麻汤合温胆汤进行方证相应的方法治疗痰湿壅盛证高血压有明显优势。
Objective
The research deployed clinical marched ran-control study, which was observed the clinical curative effect and safety of combined Pinelliae and Atractylodis Macrocephalae and Gastrodiae Decoction (PAD) and Decoction for Clearing Away Gallbladder Heat (DCH) for treating high blood pressure (HBP) with phlegmatic hygrosis flourishing syndrome patients in order to approach the clinical basement of formula and syndrome corresponding research for phlegmatic hygrosis flourishing syndrome.
Methods
To select the 60 candidates that treated in the TCM clinic service department of Chongguang in Taiwan from Nov.2008 to Dec.2009, which coincidence with the bolting standard of HBP. The diagnosis and classification of standard in western medicine was refered to the Treatment Guidance of WHO/ISH HBP 1999. The diagnosis and classification of standard in Chinese medicine was refered to Clinical Research Guidance Principle of Chinese New Drug (2000, sample version). The 60 candidates were all consistent with the standard as above, who belong to phlegmatic hygrosis flourishing syndrome andⅠ～Ⅱdegree. The patient who had secondary hypertension combined liver、brain、heart、kidney and hematopoietic system serious primarily disease was not included. Divided the candidates at the ratio of 1:1 into the treatment group and the control group randomly. The treatment group was treated with combined PAD and DCH for HBP patients with phlegmatic hygrosis flourishing syndrome. The control group was treated with Decoction of Four Mild Drugs. These two kinds of medicine that packed 9g in NO.0 Chinese medicine caps with GMP standard were all reqused at similar shape、color、package and regimen in ord to guarantee the practice of double-blind. Each group was taken 5pills at morning and evening time respectively, lmonth as a course of treatment. Before and after a course of treatment, respectively recorded the clinical symptom (dizzy、headache、heaviness of head、chest distress、spit phlegm) and blood pressure and evaluated the curative effect of symptom and high blood pressure. Observed and recorded the possible adverse effect in the treatment procedure.
Statistical methods:Database was set up with the software of Epi Data3. 1.The statistical analysis was used with the software of SPSS17.0. Two group mean comparison was observed using t-test. Matched t-test was applied for self-AP:PA comparison. The classification data was observed using 2 Test. The ranked data was observed using Ridit analysis. The software of Graph Pad Prism 4.03 was used for statistical figure.
Results
There were 60 candidates and each group was 30 cases. The ages of two groups were 57.9 years old and 60.5 years old respectively.34 cases were male and 26 cases were female. Comparability of baseline characteristics of patients in two groups of age、gender、disease course、high blood pressure staging、clinical symptom in TCM distribution and the level of blood pressure, there was no statistical significance between two groups which showed that the baseline data were comparable (P>0.05)
After a course of treatment, results of research as follows:
(1) The clinical curative effect in two groups It was showed that the excellence rate of the treatment group was 23.3%, and the effective rate was 63.3%, the total effective rate was 86.7%. While in the control group, the excellence rate of the treatment group was 10%, and the effective rate was 66.7%, the total effective rate was 76.7%. It was showed that the excellence rate of the treatment group was 23.3%, and the effective rate was 63.3%, the total effective rate was 86.7%. While in the control group, the excellence rate of the treatment group was 10%, and the effective rate was 66.7%, the total effective rate was 76.7%. There was not significant difference between two groups of symptom effect in TCM (P>0.05).It was presented that these two groups had good effect on improving the total effect score in TCM symptom. Athough there was not statistically significant, it was showed that there was effective of treating phlegmatic hygrosis flourishing syndrome with TCM.
(2)The hypertension curative effect in two groups
The hypertension curative effect after I stage:It was showed that the excellence rate of the treatment group was 20.0%, and the effective rate was 50.0%, the total effective rate was70.0%. While in the control group, the excellence rate of the treatment group was 0%, and the effective rate was28.6%, the total effective rate was 28.6%. The total effective rate was 40% highter than the control group, although there was not statistically significant, it showed that there was more effective of treating in Pinelliae and Atractylodis Macrocephalae and Gastrodiae Decoction than Decoction of Four Mild Drugs in degrading blood pressurein II stage.
The hypertension curative effect after II stage:It was showed that the excellence rate of the treatment group was 5.0%, and the effective rate was 80.0%, the ineffective rate was70.0%. While in the control group, the excellence rate of the treatment group was 0%, and the effective rate was43.5%, the total effective rate was 43.5%. Compare with the two groups, there was statistically significant (P<0.05), it showed that there was more effective of treating in the II stage in treatment group than the control group. It shows that the Pinelliae and Atractylodis Macrocephalae and Gastrodiae Decoction plus Decoction for Clearing Away Gallbladder Heat have excellence effective in degrading blood pressure in II stage.
(3) The improvement extent and the disappearance situation of the clinical symptom
In the treatment group, the patients who had improved more than 1 degree extent in dizzy、headache、heaviness of head、chest distress、spit phlegm and insomnia were account for 90.0%、96.3%、88.5%、90.0%、80.0%、50.0%、95.5% respectively after treatment, while in the control group for 48.0%、57.1%、78.3%、83.3%、50.0%、23.1%、47.6% respectively. There was statistical significance between two groups in dizzy、headache、heaviness of head、chest distress、and insomnia(P<0.01). The treatment group was better then the control group. There was not statistical significance between two groups in spit phlegm and cardiopalmus (P>0.05).It was presented that the treatment group had more significant effect than the control group on improving the clinical symptom for HBP patients with phlegmatic hygrosis flourishing syndrome, especially on heaviness of head and heaviness of head.
The disappearance rate of dizzy、headache、heaviness of head、chest distress and insomnia in treatment group was higher then that of the control group (P<0.05). while there was not statistical significance between two groups in spit phlegm and cardiopalmus (P>0.05).It was showed that the effect of combined PAD and DCH for treating HBP patients with phlegmatic hygrosis flourishing syndrome was better than Decoction of Four Mild Drugs.
(4) the changeable situation of systolic blood pressure and diastolic blood pressure at the AP:PA treatment time
After treatment, the diastolic blood pressure of the treatment group averagely decreased 2.86±1.14 kpa and there was significant difference compared with at the before and after treatment time (P<0.05). There was statistical significance in diastolic blood pressure between two groups (P<0.05). It was considered that these two groups could decrease the systolic blood pressure and diastolic blood pressure. The treatment group was better then the control group, especially at the treatment before.
(5) The situation of blood pressure back to normal
It was showed that there was 83.3% patients of blood pressure had back to normal with the evalution stardurd of blood pressure was≥21.3Kpa and/or diastolic blood pressure was≥12.7, while of which in the control group was 30.0%. There was statistical significance wihin the rate of blood pressure back to normal between two groups. The treatment group was better then the control group.
The results of safety evaluation:there was not any adverse effect at the periold of before and after treatment.
Conclusion
1. Combined PAD and DCH had the same effect on the HBP patients with phlegmatic hygrosis flourishing syndrome in different stage, alos had the effect on the improvement of the systolic blood pressure and diastolic blood pressure.
2. Combined PAD and DCH could effectively improve the symptom of the HBP patients with phlegmatic hygrosis flourishing syndrome, especially for dizzy、headache、heaviness of head、chest distress、spit phlegm and insomnia.
3. Combined PAD and DCH could effectively curing dizzy and headache of two cardinal symptoms.
4. It was safe that combined PAD and DCH for treating the HBP patients with phlegmatic hygrosis flourishing syndrome, which had more obviously advantage than Decoction of Four Mild Drugs.
本临床采用双盲随机对照试验,探讨半夏白术天麻汤合温胆汤加减治疗高血压痰湿壅盛证的临床有效性和安全性,进而为痰湿壅盛证方证相应研究提供临床依据。
方法
研究对象选取自2008年11月至2009年12月到台湾崇光中医门诊就诊的高血压病人60例。西医诊断按照《1999年WHO／ISH高血压治疗指南》中的高血压病诊断及分级标准执行；中医诊断参照2000年《中医新药临床研究指导原则》(试行)中的高血压病辨证标准及中医症状分级量化标准。以痰湿壅盛型为主证的高血压病患者60例均符合上述诊断标准,分级属Ⅰ～Ⅱ级。排除继发性高血压,合并有肝、脑、心、肾和造血系统严重原发疾病者。按照1：1的比例采用简单随机法实施随机分组,治疗组采用与痰湿壅盛证相对应的半夏白术天麻汤合温胆汤加减治疗,对照组采用不对证的四君子汤治疗。两种方药均按照一日份9克装在0号胶囊里制成GMP科学中药胶囊,要求两组药物的外形、颜色、包装、服法基本一致,以保证双盲的实施。两组患者早晚各服5粒(相当于生药4.5g),1月为1个疗程。治疗前、治疗1疗程后,分别记录高血压患者的临床症状体征(眩晕、头痛、头重如裹、胸闷、呕吐痰涎等)和血压,并进行中医证候疗效和高血压疗效评定。在临床试验过程中,密切观察可能出现的不良反应症状,并须如实记录。
数据处理方法：统计方法：分类资料用χ2检验,等级资料用两样本比较采用Ridit分析,两样本均数比较用t检验,自身前后比较用配对t检验。采用Epi Data3.01软件建立数据库,SPSS17.0软件进行统计分析,Graph Pad Prism4.03软件进行统计图形绘制。
结果
本研究共有合格受试者例60例,治疗组和对照组各30例,两组平均年龄分别为57.9和60.5岁,男34例,女26例。两组治疗前年龄、性别、病程、高血压分期及中医临床症状体征分布、血压水平(收缩压、舒张压)比较,差异均无统计学意义(P>0.05)。说明两组治疗前的基线基本一致,具有可比性。
经过一个疗程的治疗后,疗效结果比较如下：
(1)两组中医证候疗效
治疗组显效率23.3%,有效率63.3%,总有效率86.7%；对照组显效率10%,有效率66.7%,总有效率76.7%。两组中医证候疗效比较,差异无统计学意义(P>0.05)。说明治疗组和对照组在改善中医症候总体疗效评分上均有较好的疗效,虽然两组之间没有差异,但说明了中医药对治疗痰湿壅盛证高血压的有效性。
(2)两组高血压疗效
Ⅰ期高血压治疗后疗效：治疗组显效率20.0%,有效率50.0%,总有效率70.0%；对照组显效率0%,有效率28.6%,总有效率28.6%。治疗组的总有效率高于对照组近45个百分点,尽管没有统计学差异,但说明半夏白术天麻汤合温胆汤相对于四君子汤,在降低Ⅰ期高血压患者血压方面略有优势。
Ⅱ期高血压治疗后疗效：第Ⅱ期高血压治疗后疗效：治疗组显效率5.0%,有效率80.0%,无效15.0%；对照组显效率0%,有效率43.5%,总有效率43.5%,两组疗效比较,差异有统计学意义(P<0.05)。治疗组治疗Ⅱ期高血压的总有效率显著高于对照组。说明半夏白术天麻汤+温胆汤可以有效降低Ⅱ期高血压。(3)临床症状体征改善程度及消失情况
治疗组治疗后,眩晕、头痛、头重如裹、胸闷、呕吐痰涎、心悸、失眠改善1级以上的高血压患者分别占90.0%、96.3%、88.5%、90.0%、80.0%、50.0%、95.5%,对照组分别为48.0%、57.1%、78.3%、83.3%、50.0%、23.1%、47.6%。两组比较,治疗组和对照组在眩晕、头痛、头重如裹、胸闷、失眠症状方面具有统计学意义(P<0.01),以治疗组疗效较好。而在呕吐痰涎、心悸方面无统计学意义(P>0.05)。可见治疗组对痰湿壅盛证高血压的临床症状体征改善均较为显著,对照组对上述症状也均有一定的改善,尤其是对头重如裹、胸闷改善较好。
临床症状消失率比较,治疗组眩晕、头痛、头重如裹、胸闷、失眠症状消失率均高于对照组(均P<0.05)；呕吐痰涎、心悸、症状消失率治疗组虽比对照组稍高,但经比较差异均无统计学意义(均P>0.05)。由此可知,半夏白术天麻汤合温胆汤加减在改善高血压痰湿壅阻型的临床症状体征均比四君子汤疗效好。
(4)治疗前后收缩压、舒张压改变情况
治疗后收缩压,治疗组平均下降2.80±2.02kpa,前后比较差异显著(P<0.01)；对照组收缩压平均下降0.80±0.32 kpa,前后比较差异有统计学意义(P<0.05)；两组组间比较,差异有统计意义(P<0.01)。
治疗后舒张压,治疗组平均下降2.86±1.14 kpa,前后比较差异显著(P<0.01)；对照组平均下降0.76±0.71 kpa,前后比较差异有统计学意义(P<0.05)；两组治疗后舒张压比较,差异有统计意义(P<0.05)。
两组均能降低高血压患者的收缩压和舒张压,治疗组比对照组疗效略高一筹。特别是治疗前后疗效显著。
(5)血压恢复正常情况
以收缩压≥21.3Kpa或／和舒张压≥12.7为标准来评价血压是否恢复正常,结果发现治疗组83.3%的患者血压恢复正常,对照组为30.0%,两组血压恢复正常的比率差异有统计学意义(P<0.01)。治疗组优于对照组,这应该就是应用方证相应的结果。
安全性评价结果：治疗前后及治疗期间均无发现任何不良反应。
结论
1.半夏白术天麻汤合温胆汤对痰湿壅盛证高血压病不同分期的疗效相似。对收缩期和舒张期的血压均有效。
2.半夏白术天麻汤合温胆汤能够有效改善痰湿壅盛证高血压病临床常见症状,特别是眩晕、头痛、头重、胸闷、呕吐痰涎、失眠等临床症状。
3.半夏白术天麻汤合温胆汤能够有效消除眩晕和头痛这两个高血压病的主要症状。
4.半夏白术天麻汤合温胆汤治疗痰湿壅盛证高血压病具有安全有效的特点,同时与四君子汤相比,应用半夏白术天麻汤合温胆汤进行方证相应的方法治疗痰湿壅盛证高血压有明显优势。
Objective
The research deployed clinical marched ran-control study, which was observed the clinical curative effect and safety of combined Pinelliae and Atractylodis Macrocephalae and Gastrodiae Decoction (PAD) and Decoction for Clearing Away Gallbladder Heat (DCH) for treating high blood pressure (HBP) with phlegmatic hygrosis flourishing syndrome patients in order to approach the clinical basement of formula and syndrome corresponding research for phlegmatic hygrosis flourishing syndrome.
Methods
To select the 60 candidates that treated in the TCM clinic service department of Chongguang in Taiwan from Nov.2008 to Dec.2009, which coincidence with the bolting standard of HBP. The diagnosis and classification of standard in western medicine was refered to the Treatment Guidance of WHO/ISH HBP 1999. The diagnosis and classification of standard in Chinese medicine was refered to Clinical Research Guidance Principle of Chinese New Drug (2000, sample version). The 60 candidates were all consistent with the standard as above, who belong to phlegmatic hygrosis flourishing syndrome andⅠ～Ⅱdegree. The patient who had secondary hypertension combined liver、brain、heart、kidney and hematopoietic system serious primarily disease was not included. Divided the candidates at the ratio of 1:1 into the treatment group and the control group randomly. The treatment group was treated with combined PAD and DCH for HBP patients with phlegmatic hygrosis flourishing syndrome. The control group was treated with Decoction of Four Mild Drugs. These two kinds of medicine that packed 9g in NO.0 Chinese medicine caps with GMP standard were all reqused at similar shape、color、package and regimen in ord to guarantee the practice of double-blind. Each group was taken 5pills at morning and evening time respectively, lmonth as a course of treatment. Before and after a course of treatment, respectively recorded the clinical symptom (dizzy、headache、heaviness of head、chest distress、spit phlegm) and blood pressure and evaluated the curative effect of symptom and high blood pressure. Observed and recorded the possible adverse effect in the treatment procedure.
Statistical methods:Database was set up with the software of Epi Data3. 1.The statistical analysis was used with the software of SPSS17.0. Two group mean comparison was observed using t-test. Matched t-test was applied for self-AP:PA comparison. The classification data was observed using 2 Test. The ranked data was observed using Ridit analysis. The software of Graph Pad Prism 4.03 was used for statistical figure.
Results
There were 60 candidates and each group was 30 cases. The ages of two groups were 57.9 years old and 60.5 years old respectively.34 cases were male and 26 cases were female. Comparability of baseline characteristics of patients in two groups of age、gender、disease course、high blood pressure staging、clinical symptom in TCM distribution and the level of blood pressure, there was no statistical significance between two groups which showed that the baseline data were comparable (P>0.05)
After a course of treatment, results of research as follows:
(1) The clinical curative effect in two groups It was showed that the excellence rate of the treatment group was 23.3%, and the effective rate was 63.3%, the total effective rate was 86.7%. While in the control group, the excellence rate of the treatment group was 10%, and the effective rate was 66.7%, the total effective rate was 76.7%. It was showed that the excellence rate of the treatment group was 23.3%, and the effective rate was 63.3%, the total effective rate was 86.7%. While in the control group, the excellence rate of the treatment group was 10%, and the effective rate was 66.7%, the total effective rate was 76.7%. There was not significant difference between two groups of symptom effect in TCM (P>0.05).It was presented that these two groups had good effect on improving the total effect score in TCM symptom. Athough there was not statistically significant, it was showed that there was effective of treating phlegmatic hygrosis flourishing syndrome with TCM.
(2)The hypertension curative effect in two groups
The hypertension curative effect after I stage:It was showed that the excellence rate of the treatment group was 20.0%, and the effective rate was 50.0%, the total effective rate was70.0%. While in the control group, the excellence rate of the treatment group was 0%, and the effective rate was28.6%, the total effective rate was 28.6%. The total effective rate was 40% highter than the control group, although there was not statistically significant, it showed that there was more effective of treating in Pinelliae and Atractylodis Macrocephalae and Gastrodiae Decoction than Decoction of Four Mild Drugs in degrading blood pressurein II stage.
The hypertension curative effect after II stage:It was showed that the excellence rate of the treatment group was 5.0%, and the effective rate was 80.0%, the ineffective rate was70.0%. While in the control group, the excellence rate of the treatment group was 0%, and the effective rate was43.5%, the total effective rate was 43.5%. Compare with the two groups, there was statistically significant (P<0.05), it showed that there was more effective of treating in the II stage in treatment group than the control group. It shows that the Pinelliae and Atractylodis Macrocephalae and Gastrodiae Decoction plus Decoction for Clearing Away Gallbladder Heat have excellence effective in degrading blood pressure in II stage.
(3) The improvement extent and the disappearance situation of the clinical symptom
In the treatment group, the patients who had improved more than 1 degree extent in dizzy、headache、heaviness of head、chest distress、spit phlegm and insomnia were account for 90.0%、96.3%、88.5%、90.0%、80.0%、50.0%、95.5% respectively after treatment, while in the control group for 48.0%、57.1%、78.3%、83.3%、50.0%、23.1%、47.6% respectively. There was statistical significance between two groups in dizzy、headache、heaviness of head、chest distress、and insomnia(P<0.01). The treatment group was better then the control group. There was not statistical significance between two groups in spit phlegm and cardiopalmus (P>0.05).It was presented that the treatment group had more significant effect than the control group on improving the clinical symptom for HBP patients with phlegmatic hygrosis flourishing syndrome, especially on heaviness of head and heaviness of head.
The disappearance rate of dizzy、headache、heaviness of head、chest distress and insomnia in treatment group was higher then that of the control group (P<0.05). while there was not statistical significance between two groups in spit phlegm and cardiopalmus (P>0.05).It was showed that the effect of combined PAD and DCH for treating HBP patients with phlegmatic hygrosis flourishing syndrome was better than Decoction of Four Mild Drugs.
(4) the changeable situation of systolic blood pressure and diastolic blood pressure at the AP:PA treatment time
After treatment, the diastolic blood pressure of the treatment group averagely decreased 2.86±1.14 kpa and there was significant difference compared with at the before and after treatment time (P<0.05). There was statistical significance in diastolic blood pressure between two groups (P<0.05). It was considered that these two groups could decrease the systolic blood pressure and diastolic blood pressure. The treatment group was better then the control group, especially at the treatment before.
(5) The situation of blood pressure back to normal
It was showed that there was 83.3% patients of blood pressure had back to normal with the evalution stardurd of blood pressure was≥21.3Kpa and/or diastolic blood pressure was≥12.7, while of which in the control group was 30.0%. There was statistical significance wihin the rate of blood pressure back to normal between two groups. The treatment group was better then the control group.
The results of safety evaluation:there was not any adverse effect at the periold of before and after treatment.
Conclusion
1. Combined PAD and DCH had the same effect on the HBP patients with phlegmatic hygrosis flourishing syndrome in different stage, alos had the effect on the improvement of the systolic blood pressure and diastolic blood pressure.
2. Combined PAD and DCH could effectively improve the symptom of the HBP patients with phlegmatic hygrosis flourishing syndrome, especially for dizzy、headache、heaviness of head、chest distress、spit phlegm and insomnia.
3. Combined PAD and DCH could effectively curing dizzy and headache of two cardinal symptoms.
4. It was safe that combined PAD and DCH for treating the HBP patients with phlegmatic hygrosis flourishing syndrome, which had more obviously advantage than Decoction of Four Mild Drugs.
引文
[1]叶任高,陆再英.内科学[M].第6版.北京：人民卫生出版社,2004：247.
[2]朱金妹.近10年中医药治疗原发性高血压方证对应的现代文献分析[J].山东中医药大学学报,2009,33(2)：116-117.
[3]吴启锋,茂祥,东辉.半夏白术天麻汤对痰湿壅盛型高血压病盐敏感性及血脂水平的影响[J].福建医药杂志,2007,29(1)：146-148.
[4]李丽,王慧娟.半夏的药理和临床研究进展[J].中医药信息,2006,23(5)：38.
[5]欧仕益.橘皮营的药理作用[J].中药材,2002,25(7)：531.
[6]欧兴长,丁家欣,张玲.枳实等几种中药体外抗血栓作用研究[J].中西医结合杂志,1989,9(6)：358-359.
[7]吉中强,宋鲁卿,高晓听,等.11种中药对大鼠血小板聚集和红细胞流变性的影响[J].山东中医杂志,2000,(2)19：107.
[8]FuhrmanB VolkovaN. Antiatherose lerotic effeets of lieorie extracts suPPlenmentation on hyPercholestero lemic Patients:in 2creased resistancev of LDL to atherogenie modifieations, reduee Plasmali Pidlevels, and deereased systolie blood Pressure. Nutrition,2002,18: 268-273.
[9]钟治美.高血压病中医分型及治法明[J].新中医,1996,11：61-62.
[10]王星田.高血压病中医证治探讨明[J].河南中医,2003,23(8)：59-60.
[11]胡世云,冼绍样,赵立诚,等.高血压病中医治法的临床研究进展[J].新中医,2003,35(1)：69-71.
[12]满广博.天麻钩藤汤加减治疗高血压病110例[J].辽宁中医杂志,2005,32(6)：552.
[13]章伟明.温胆汤新用[J].新中医,2001,11(9)：65.
[14]李玉春.龙胆泻肝汤治疗高血压病136例[J].湖南中医杂志,1998,14(3)：47.
[15]李西秦.补肾为主治疗家族性高血压病30例[J].陕西中医,2002,211(9)：393.
[16]吴平.补中益气加减治疗单纯收缩期高血压初探[J].铁道医学,2001,29(1)：63.
[17]齐冬梅,石作荣.活血化瘀法治疗老年人高血压35例[J].山东中医药大学学报,1999,23(1)：41-43.
[18]袁成民,丁书文.八物降压冲剂治疗原发性高血压的临床及实验研究[J].山东 中医药大学学报,1999,23(3)：1889-1920.
[19]刘见,贾琳娜.中医治疗高血压病的方药[J].中国临床医生,1999,27(12)：717-719.
[20]李秀才.高血压病的中医中药治疗[J].现代诊断与治疗,1996,7(1)7-9.
[21]陈子江.血灵对高血压病人血粘度的影响[J].中药,1994,16：287.
[22]杨霓芝.降压方治疗高血压病疗效观察[J].新中医,1994,26：288.
[23]王达平.水蛭土元粉治疗轻中型高血压病32例观察[J].中国中西医结合杂志,1992,12：389.
[24]刘华.仙柏补阳还五汤治疗肾气虚血瘀型高血压病的临床研究[J].中国中西医结合杂志,1993,13：714.
[25]丁青.潜熄宁治疗阴虚阳亢型高血压病60例临床研究[J].中国中西医结合杂志,1992,12：405.
[26]吕国良.复方黄瓜藤片治疗高血压病的临床及实验研究[J].中西医结合杂志,1991,11：274.
[27]史载祥,黄柳华.高血压及相关疾病中西医结合诊治[M].北京：人民卫生出版社,2003：222-224.
[28]周超凡,陈京莉.中医治疗高血压病的用药思路与方法[J].中国中医药信息杂志,2003,10(4)：72-73
[29]刘吉.中医外治法治疗高血压病阴[J].辽宁中医杂志,2002,29(4)：217.
[30]骆传江,徐华龙.中医推拿与西药治疗高血压各50例临床观察[J].按摩与导引,2002,1(1)：16-17.
[31]王炳阳.中药降压贴治疗高血压病30例[J].中国中医药科技,2004,11(5)：315-317.
[32]温长路,陈冰,温武兵,等.国药降压健身浴醋的临床研明[J].河南中医,1998,18(4)：219.
[33]卓一高.血压的中医预防与保健明[J].中国社区医师,2004,20(251)：43.
[34]王阶,荆鲁,王永炎.相同治法不同配伍对冠心病心绞痛疗效及客观指标的影响[J].云南中医学院学报,2004,27(4)：1-5.
[35]谢鸣.“方证相关性”逻辑命题及其意义[J].北京中医药大学学报,2003,26(2)：11.
[36]李瑞,尹英杰,林毅,等.中医方证客观化研究初探[J].北京中医药大学学报,2002,25(3)：6.
[37]刘渡舟.方证相对论[J].北京中医药大学学报,1996,19(1)：3-5.
[38]章梅,夏天,张仲海,等.四君子汤对脾虚患者血浆细胞因子的影响田[J].第四军医大学学报,1996,21(4)：411-413.
[39]魏彦明,李文广.实验性脾虚证与自由基代谢的相关性及四君子汤对其的调整作用田[J].畜牧兽医学报,2002,33(1)：404-407.
[40]魏彦明,宗瑞谦,杨孝朴.实验性脾虚证大鼠血浆胃泌素和胃动素含量变化及四君子汤对其调整作用[J].中国兽医学报,2001,21(3)：281-283.
[41]朱邦贤.方剂辨证与方证规范化之我见[J].上海中医药杂志,1997,11：2-5.
[42]田金洲,王永炎,时晶,等.证候的概念及其属性[J].北京中医药大学学报2003,5(28)：6-8.
[43]林坚.试论中医学方证相应观[J].中国中医基础医学杂志,2000,6(7)：9-11.
[44]马丽红,焦增锦,张瑞华.心血虚的客观化研究进展[J].中国中医基础医学杂志,1999,5(5)：59.
[45]陈家旭.中医证实质研究存在的问题与对策[J].医学与哲学,1995,16(3)：131-132.
[46]顾武军.《伤寒论》方临床运用刍议[J].南京中医药大学学报,1999,15(6)：321-323.
[47]章凤杰,吴悦.高血压病经颅多普勒检测结果与辨证分型关系探讨[J].江苏中医,1997,18(8)：41.
[48]郭冀珍.高血压治疗的新进展[J].中华内科杂志,1997,36(9)：638.
[49]The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, andTreatment ofHighBlood Pressure:the JNC 7 report[J]. JAMA,2003,289 (3):2560-2572.
[50]Wang C, Chao L, et al. Direct gene delivery ofhuman tissue kallikrei reduces blood pressure in spontaneously hypertensive rats [J]. EHEP report, 1995,95 (4):1710-1716.
[51]Ravera M, Berrativ, et al. Optinizing therapy in the diabetic patient with renal disease antihy pertensive treatment [J]. J Am Soc Nephro,1996, 15 (1):56.
[52]Levine CE, NeldamS, Tikkanen I et al. the candesartan and Lisino. pill microalbum inufia study[J]. BMJ,2001,3219 (5):1440-1444.
[53]Welidler MJ, Katovich MJ, Wang H, et al. Isantisense gene therapy a step inthe fight direction in the control of hypertension [J]. Am J Physiol, 1999,277 (2):423-432.
[54]张静,刘洋.高血压病人的用药指导[J].社区医学杂志,2006,4(8)：24-26.
[55]Moensen CE, NeldamS, Tikkanen I, ct al. The candesartan and Lisinopril microalbum inuria (CLAM) study[J]. BMJ,2001,321 (3):1440-1444.
[56]Yusuf S,Sleisht P,]Pogue J,et al. Effects of an angiotensin-conveYting-enzyme inhibitor, ramipfil, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigations. N Engl J Med,2000,342 (3):145-153.
[57]Martinez JA, Oconnor DT. Somatic cell gene therapy for 8 trait as complex a8 hypertension[J]. Clin Invest,1995,95 (4):1426.
[58]郭玲,王丽华,李霞,等.RAS系统抑制剂治疗高血压的研究进展[J].社区医学杂志,2006,4(6)：39-41.
[59]唐伟,崔岱.肾素-血管紧张素-醛固酮系统阻滞剂在糖尿病心血管并发症中的应用[J].国外医学药学分册,2004,31(5)：292-295.
[60]Neil AH, David S. Genetic testing and public policy[J]. The new genetics, 1998,316 (7):852-856.
[61]Zuckerbraun BS, Chin BY, Wegiel B, ct al. Carbon monoxide rever-SCB established pulmonary hypertension [J]. Exp Med,2006,203(9):2109-2119.
[62]郭利,刘刚.多肽类似物一类肽和假肽的研究进展[J].国外医学药学分册,1995,22(5)：261.
[63]Gerstein H C. Effects of ramipril on cardiovascular and miemvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICPOHOPE substudy. Heart outcomes prevention evaluation audy investigations. Lancet,2000,355 (9200):253-259.
[64]土桥卓也,藤岛正敏.Ca拮抗药[J].临床研究,2003,80(1)：35-38.
[65]孙立群,宁桂兰.氨氯地平与依那普利治疗社区老年1、2级原发性高血压的治疗比较[J].药物与临床,2006,14(5)：552-553.
[66]AROSIOE, DEMARCHIS, PRIOR M, et al. Efects of nebivolol and atenolol onsmall arteries and mien) circulatory endothelim-de--pendent dilmion in hype~en-sive patients undergoing isometric stress. J Hype~ens,2002,20 (9):1707-1709.
[67]WILKINSON IB, QASEMA, MCENIERYCM, et al. Nitric oxideregulates local arterial distensibility in vivo. Ciulmion,2002,105 (2):213-217.
[68]郭利,恽榴红.含硒化合物研究进展[J].中国新药杂志,2000,9(3)：155-158.
[69]李卫杰,陈红,苏定冯.髓脂素[J].生理科学进展,1994,25(4)：7-9.
[70]郑筱萸.中药新药临床研究指到原则[S].北京：中国医药科技出版社,2002：74,76,77.
[71]刘青云,王树荣,张大方等.中药药理学(第二版)[M].北京：人民卫生出版社,2002,2：208-210.
[72]杨虹,俞桂新,王峥涛,等.半夏的化学成分研究[J].中国药学杂志,2007,42(2)：99-101.
[73]何萍,李帅,王素娟,杨永春,等.半夏化学成分的研究[J].中国中药杂志,2005,3(9)：671-674.
[74]李玉先,刘晓东,朱照静.半夏药理作用的研究述要[J].辽宁中医学院学报,2004,6(6)：459-460.
[75]李忠红,聂晶,倪坤仪,等.不同产地半夏的化学成分分析及比较[J].分析科学学报,2005,21(4)：393-395.
[76]丁安伟.现代中药临床手册[M].南京：江苏科学技术出版社,2000：182-183.
[77]余上才,章育正.白术的免疫调节作用[J].上海免疫学杂志,2001,11(1)：14-15.
[78]窦有业,王薇.茯苓及羧甲基茯苓多糖的研究概况[J].中国药师,2005,3(8)：123-124.
[79]孙媛.竹茹现代研究概况[J].黑龙江中医药.2008,21(6)：78-79.
[80]刘彬,齐云.甘草酸及甘草次酸的药理学研究进展[J].国外医药·植物药分册,2006,21(3)：100-104.
[81]张国华.赵立诚从痰论治原发性高血压病经验[J].浙江中医杂志,2006,41(4)：206-207.
[82]朱妍,韩学杰.高血压病从痰瘀论治的理论研究[J].2006,4(10)：890-891.
[83]冯向阳.辨证分型治疗高血压病112例临床观察[J].中医药导报,2006,12(8)：34-36.
[84]张发荣.高血压病气虚血瘀型特征探析：附357例临床资料[J].江苏中医,1997,18(9)：38-39.
[85]邓椿松.辨证治疗高血压病127例[J].吉林中医药,2001,21(2)：17.
[86]魏霞,穆广梅.辨证论治治疗高血压病300例[J].中医研究,2003,16(4)：57-58.
[87]蔡光先,朱克俭,韩育明,等.高血压病常见证候临床流行病学观察[J].中医杂志,1999,40(8)：492-493.
[88]周文泉,于向东,崔玲,等.部分高血压病患者证候和危险因素调查[J].中国中西医结合杂志,2002,22(6)：457-458.
[89]程文江,郭峰,毛军民.原发性高血压病602例中医证候流行病学研究[J].浙江中西医结合杂志,2003,13(4)：261-262.
[90]郑峰,胡世云,郭进建,等.高血压病中医辨证分析[J].河北中医,2000,22(9)：651-653.
[91]林炳辉,方素钦,邱山东,等.高血压病中医分型与动态血压、血浆内皮素及降 钙素基因相关肽水平的关系[J].福建中医学院学报,2002,12(12)：6-8.
[92]黄俊山,白介辰,黄国良,等.高血压病患者血清胰岛素、C肽水平与中医辨证分型的关系[J].中国中西医结合杂志,2000,20(3)：190-191.
[93]陈启后,周国兰.高血压病患者辨证分型与血液流变学及血脂关系的研究[J].湖南中医杂志,1990,6(2)：3-5.
[94]梁东辉.高血压病中医辨证分型与血脂水平关系的探讨[J].辽宁中医杂志,1996,23(4)：148-149.
[95]郑新,刘卫红.高血压病中医辨证分型的血压变化及胸主动脉CT改变的研究[J].中国中西医结合杂志,1997,17(12)：733-734.
[96]刘健.经颅多普勒与高血压病辨证分型的关系[J].南京中医药大学学报,1997,13(5)：272-273.
[97]蒲昭和.别把天麻当做补药吃[J].养生月刊,2006,27(3)：230-231.
[98]杨世林,兰进,徐锦堂.天麻的研究进展[J].中草药,2000,31(1)：66-69.
[2]朱金妹.近10年中医药治疗原发性高血压方证对应的现代文献分析[J].山东中医药大学学报,2009,33(2)：116-117.
[3]吴启锋,茂祥,东辉.半夏白术天麻汤对痰湿壅盛型高血压病盐敏感性及血脂水平的影响[J].福建医药杂志,2007,29(1)：146-148.
[4]李丽,王慧娟.半夏的药理和临床研究进展[J].中医药信息,2006,23(5)：38.
[5]欧仕益.橘皮营的药理作用[J].中药材,2002,25(7)：531.
[6]欧兴长,丁家欣,张玲.枳实等几种中药体外抗血栓作用研究[J].中西医结合杂志,1989,9(6)：358-359.
[7]吉中强,宋鲁卿,高晓听,等.11种中药对大鼠血小板聚集和红细胞流变性的影响[J].山东中医杂志,2000,(2)19：107.
[8]FuhrmanB VolkovaN. Antiatherose lerotic effeets of lieorie extracts suPPlenmentation on hyPercholestero lemic Patients:in 2creased resistancev of LDL to atherogenie modifieations, reduee Plasmali Pidlevels, and deereased systolie blood Pressure. Nutrition,2002,18: 268-273.
[9]钟治美.高血压病中医分型及治法明[J].新中医,1996,11：61-62.
[10]王星田.高血压病中医证治探讨明[J].河南中医,2003,23(8)：59-60.
[11]胡世云,冼绍样,赵立诚,等.高血压病中医治法的临床研究进展[J].新中医,2003,35(1)：69-71.
[12]满广博.天麻钩藤汤加减治疗高血压病110例[J].辽宁中医杂志,2005,32(6)：552.
[13]章伟明.温胆汤新用[J].新中医,2001,11(9)：65.
[14]李玉春.龙胆泻肝汤治疗高血压病136例[J].湖南中医杂志,1998,14(3)：47.
[15]李西秦.补肾为主治疗家族性高血压病30例[J].陕西中医,2002,211(9)：393.
[16]吴平.补中益气加减治疗单纯收缩期高血压初探[J].铁道医学,2001,29(1)：63.
[17]齐冬梅,石作荣.活血化瘀法治疗老年人高血压35例[J].山东中医药大学学报,1999,23(1)：41-43.
[18]袁成民,丁书文.八物降压冲剂治疗原发性高血压的临床及实验研究[J].山东 中医药大学学报,1999,23(3)：1889-1920.
[19]刘见,贾琳娜.中医治疗高血压病的方药[J].中国临床医生,1999,27(12)：717-719.
[20]李秀才.高血压病的中医中药治疗[J].现代诊断与治疗,1996,7(1)7-9.
[21]陈子江.血灵对高血压病人血粘度的影响[J].中药,1994,16：287.
[22]杨霓芝.降压方治疗高血压病疗效观察[J].新中医,1994,26：288.
[23]王达平.水蛭土元粉治疗轻中型高血压病32例观察[J].中国中西医结合杂志,1992,12：389.
[24]刘华.仙柏补阳还五汤治疗肾气虚血瘀型高血压病的临床研究[J].中国中西医结合杂志,1993,13：714.
[25]丁青.潜熄宁治疗阴虚阳亢型高血压病60例临床研究[J].中国中西医结合杂志,1992,12：405.
[26]吕国良.复方黄瓜藤片治疗高血压病的临床及实验研究[J].中西医结合杂志,1991,11：274.
[27]史载祥,黄柳华.高血压及相关疾病中西医结合诊治[M].北京：人民卫生出版社,2003：222-224.
[28]周超凡,陈京莉.中医治疗高血压病的用药思路与方法[J].中国中医药信息杂志,2003,10(4)：72-73
[29]刘吉.中医外治法治疗高血压病阴[J].辽宁中医杂志,2002,29(4)：217.
[30]骆传江,徐华龙.中医推拿与西药治疗高血压各50例临床观察[J].按摩与导引,2002,1(1)：16-17.
[31]王炳阳.中药降压贴治疗高血压病30例[J].中国中医药科技,2004,11(5)：315-317.
[32]温长路,陈冰,温武兵,等.国药降压健身浴醋的临床研明[J].河南中医,1998,18(4)：219.
[33]卓一高.血压的中医预防与保健明[J].中国社区医师,2004,20(251)：43.
[34]王阶,荆鲁,王永炎.相同治法不同配伍对冠心病心绞痛疗效及客观指标的影响[J].云南中医学院学报,2004,27(4)：1-5.
[35]谢鸣.“方证相关性”逻辑命题及其意义[J].北京中医药大学学报,2003,26(2)：11.
[36]李瑞,尹英杰,林毅,等.中医方证客观化研究初探[J].北京中医药大学学报,2002,25(3)：6.
[37]刘渡舟.方证相对论[J].北京中医药大学学报,1996,19(1)：3-5.
[38]章梅,夏天,张仲海,等.四君子汤对脾虚患者血浆细胞因子的影响田[J].第四军医大学学报,1996,21(4)：411-413.
[39]魏彦明,李文广.实验性脾虚证与自由基代谢的相关性及四君子汤对其的调整作用田[J].畜牧兽医学报,2002,33(1)：404-407.
[40]魏彦明,宗瑞谦,杨孝朴.实验性脾虚证大鼠血浆胃泌素和胃动素含量变化及四君子汤对其调整作用[J].中国兽医学报,2001,21(3)：281-283.
[41]朱邦贤.方剂辨证与方证规范化之我见[J].上海中医药杂志,1997,11：2-5.
[42]田金洲,王永炎,时晶,等.证候的概念及其属性[J].北京中医药大学学报2003,5(28)：6-8.
[43]林坚.试论中医学方证相应观[J].中国中医基础医学杂志,2000,6(7)：9-11.
[44]马丽红,焦增锦,张瑞华.心血虚的客观化研究进展[J].中国中医基础医学杂志,1999,5(5)：59.
[45]陈家旭.中医证实质研究存在的问题与对策[J].医学与哲学,1995,16(3)：131-132.
[46]顾武军.《伤寒论》方临床运用刍议[J].南京中医药大学学报,1999,15(6)：321-323.
[47]章凤杰,吴悦.高血压病经颅多普勒检测结果与辨证分型关系探讨[J].江苏中医,1997,18(8)：41.
[48]郭冀珍.高血压治疗的新进展[J].中华内科杂志,1997,36(9)：638.
[49]The Seventh Report of the Joint National Committee on Prevention Detection, Evaluation, andTreatment ofHighBlood Pressure:the JNC 7 report[J]. JAMA,2003,289 (3):2560-2572.
[50]Wang C, Chao L, et al. Direct gene delivery ofhuman tissue kallikrei reduces blood pressure in spontaneously hypertensive rats [J]. EHEP report, 1995,95 (4):1710-1716.
[51]Ravera M, Berrativ, et al. Optinizing therapy in the diabetic patient with renal disease antihy pertensive treatment [J]. J Am Soc Nephro,1996, 15 (1):56.
[52]Levine CE, NeldamS, Tikkanen I et al. the candesartan and Lisino. pill microalbum inufia study[J]. BMJ,2001,3219 (5):1440-1444.
[53]Welidler MJ, Katovich MJ, Wang H, et al. Isantisense gene therapy a step inthe fight direction in the control of hypertension [J]. Am J Physiol, 1999,277 (2):423-432.
[54]张静,刘洋.高血压病人的用药指导[J].社区医学杂志,2006,4(8)：24-26.
[55]Moensen CE, NeldamS, Tikkanen I, ct al. The candesartan and Lisinopril microalbum inuria (CLAM) study[J]. BMJ,2001,321 (3):1440-1444.
[56]Yusuf S,Sleisht P,]Pogue J,et al. Effects of an angiotensin-conveYting-enzyme inhibitor, ramipfil, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigations. N Engl J Med,2000,342 (3):145-153.
[57]Martinez JA, Oconnor DT. Somatic cell gene therapy for 8 trait as complex a8 hypertension[J]. Clin Invest,1995,95 (4):1426.
[58]郭玲,王丽华,李霞,等.RAS系统抑制剂治疗高血压的研究进展[J].社区医学杂志,2006,4(6)：39-41.
[59]唐伟,崔岱.肾素-血管紧张素-醛固酮系统阻滞剂在糖尿病心血管并发症中的应用[J].国外医学药学分册,2004,31(5)：292-295.
[60]Neil AH, David S. Genetic testing and public policy[J]. The new genetics, 1998,316 (7):852-856.
[61]Zuckerbraun BS, Chin BY, Wegiel B, ct al. Carbon monoxide rever-SCB established pulmonary hypertension [J]. Exp Med,2006,203(9):2109-2119.
[62]郭利,刘刚.多肽类似物一类肽和假肽的研究进展[J].国外医学药学分册,1995,22(5)：261.
[63]Gerstein H C. Effects of ramipril on cardiovascular and miemvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICPOHOPE substudy. Heart outcomes prevention evaluation audy investigations. Lancet,2000,355 (9200):253-259.
[64]土桥卓也,藤岛正敏.Ca拮抗药[J].临床研究,2003,80(1)：35-38.
[65]孙立群,宁桂兰.氨氯地平与依那普利治疗社区老年1、2级原发性高血压的治疗比较[J].药物与临床,2006,14(5)：552-553.
[66]AROSIOE, DEMARCHIS, PRIOR M, et al. Efects of nebivolol and atenolol onsmall arteries and mien) circulatory endothelim-de--pendent dilmion in hype~en-sive patients undergoing isometric stress. J Hype~ens,2002,20 (9):1707-1709.
[67]WILKINSON IB, QASEMA, MCENIERYCM, et al. Nitric oxideregulates local arterial distensibility in vivo. Ciulmion,2002,105 (2):213-217.
[68]郭利,恽榴红.含硒化合物研究进展[J].中国新药杂志,2000,9(3)：155-158.
[69]李卫杰,陈红,苏定冯.髓脂素[J].生理科学进展,1994,25(4)：7-9.
[70]郑筱萸.中药新药临床研究指到原则[S].北京：中国医药科技出版社,2002：74,76,77.
[71]刘青云,王树荣,张大方等.中药药理学(第二版)[M].北京：人民卫生出版社,2002,2：208-210.
[72]杨虹,俞桂新,王峥涛,等.半夏的化学成分研究[J].中国药学杂志,2007,42(2)：99-101.
[73]何萍,李帅,王素娟,杨永春,等.半夏化学成分的研究[J].中国中药杂志,2005,3(9)：671-674.
[74]李玉先,刘晓东,朱照静.半夏药理作用的研究述要[J].辽宁中医学院学报,2004,6(6)：459-460.
[75]李忠红,聂晶,倪坤仪,等.不同产地半夏的化学成分分析及比较[J].分析科学学报,2005,21(4)：393-395.
[76]丁安伟.现代中药临床手册[M].南京：江苏科学技术出版社,2000：182-183.
[77]余上才,章育正.白术的免疫调节作用[J].上海免疫学杂志,2001,11(1)：14-15.
[78]窦有业,王薇.茯苓及羧甲基茯苓多糖的研究概况[J].中国药师,2005,3(8)：123-124.
[79]孙媛.竹茹现代研究概况[J].黑龙江中医药.2008,21(6)：78-79.
[80]刘彬,齐云.甘草酸及甘草次酸的药理学研究进展[J].国外医药·植物药分册,2006,21(3)：100-104.
[81]张国华.赵立诚从痰论治原发性高血压病经验[J].浙江中医杂志,2006,41(4)：206-207.
[82]朱妍,韩学杰.高血压病从痰瘀论治的理论研究[J].2006,4(10)：890-891.
[83]冯向阳.辨证分型治疗高血压病112例临床观察[J].中医药导报,2006,12(8)：34-36.
[84]张发荣.高血压病气虚血瘀型特征探析：附357例临床资料[J].江苏中医,1997,18(9)：38-39.
[85]邓椿松.辨证治疗高血压病127例[J].吉林中医药,2001,21(2)：17.
[86]魏霞,穆广梅.辨证论治治疗高血压病300例[J].中医研究,2003,16(4)：57-58.
[87]蔡光先,朱克俭,韩育明,等.高血压病常见证候临床流行病学观察[J].中医杂志,1999,40(8)：492-493.
[88]周文泉,于向东,崔玲,等.部分高血压病患者证候和危险因素调查[J].中国中西医结合杂志,2002,22(6)：457-458.
[89]程文江,郭峰,毛军民.原发性高血压病602例中医证候流行病学研究[J].浙江中西医结合杂志,2003,13(4)：261-262.
[90]郑峰,胡世云,郭进建,等.高血压病中医辨证分析[J].河北中医,2000,22(9)：651-653.
[91]林炳辉,方素钦,邱山东,等.高血压病中医分型与动态血压、血浆内皮素及降 钙素基因相关肽水平的关系[J].福建中医学院学报,2002,12(12)：6-8.
[92]黄俊山,白介辰,黄国良,等.高血压病患者血清胰岛素、C肽水平与中医辨证分型的关系[J].中国中西医结合杂志,2000,20(3)：190-191.
[93]陈启后,周国兰.高血压病患者辨证分型与血液流变学及血脂关系的研究[J].湖南中医杂志,1990,6(2)：3-5.
[94]梁东辉.高血压病中医辨证分型与血脂水平关系的探讨[J].辽宁中医杂志,1996,23(4)：148-149.
[95]郑新,刘卫红.高血压病中医辨证分型的血压变化及胸主动脉CT改变的研究[J].中国中西医结合杂志,1997,17(12)：733-734.
[96]刘健.经颅多普勒与高血压病辨证分型的关系[J].南京中医药大学学报,1997,13(5)：272-273.
[97]蒲昭和.别把天麻当做补药吃[J].养生月刊,2006,27(3)：230-231.
[98]杨世林,兰进,徐锦堂.天麻的研究进展[J].中草药,2000,31(1)：66-69.